PYC Therapeutics (PYC) Q4 2024 earnings summary

Executive summary

• Advanced three lead drug programs toward human trials, targeting rare genetic diseases with no current treatments.

• Achieved key milestones in safety and early efficacy for Retinitis Pigmentosa type 11, and regulatory progress for Autosomal Dominant Optic Atrophy.

• Cleared preclinical safety for Polycystic Kidney Disease candidate and initiated IND-enabling studies for Phelan-McDermid Syndrome.

Financial highlights

• Ended Q2 2024 with $66.9 million in cash and cash equivalents.

• R&D payments totaled $15.3 million for the quarter, supporting clinical and regulatory activities.

• Received $16.5 million collaboration fee from an AI drug discovery project.

• Net cash used in operating activities was $16.1 million for the quarter.

• Raised $34.4 million from equity issuance, with net financing cash inflow of $33.3 million.

Outlook and guidance

• On track to deliver clinical proof-of-concept data for three advanced drug programs by end of 2025.

• Human safety and efficacy data for Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy expected in 2024.

• Clinical trials for Polycystic Kidney Disease to commence in early 2025, with data anticipated in 2025–2026.

• IND-enabling studies for Phelan-McDermid Syndrome planned for 2025.